

BIOCON PHARMA IRELAND LIMITED
BALANCE SHEET AS AT MARCH 31,2022

(All amounts in EURO, except share data and unless otherwise stated)

	<u>Note</u>	<u>March 31,2022</u>	<u>March 31, 2021</u>
ASSETS			
Non-current assets			
Intangible assets under development		1,80,779	1,14,904
Current assets			
Financial assets			
(i) Cash and cash equivalents	2	1,855	2,18,424
(ii) Other Financial Asset	2.00	2,65,707	-
Other current assets	3	300	746
Total current assets		2,67,862	2,19,170
TOTAL		4,48,641	3,34,074
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4(a)	7,75,001	7,75,001
Other equity	4(b)	(4,66,276)	(4,66,285)
Total equity		3,08,725	3,08,716
Current liabilities			
Financial liabilities			
(i) Borrowings	4	-	-
(i) Trade payables	5	1,39,916	25,358
(ii) Other financial liabilities	7	-	-
Other current liabilities	6	-	-
Total current liabilities		1,39,916	25,358
TOTAL		4,48,641	3,34,074

The accompanying notes are an integral part of the financial statements.

for and on behalf of the Board of Directors of Biocon Pharma Ireland Limited

Kiran Mazumdar-Shaw
Director
DIN: 00347229

John Shaw
Director
DIN: 00347250

BIOCON PHARMA IRELAND LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31,2022
(All amounts in EURO, except share data and unless otherwise stated)

	<u>Note</u>	Year ended March 31, 2022	Year ended March 31, 2021
Income			
Other income		9	-
Total income		9	-
Expenses			
Employee benefits expense	8	-	-
Finance Cost	8	-	-
Other expenses	6	-	2,60,369
Total expenses		-	2,60,369
Profit/(Loss) before tax		9	(2,60,369)
Tax expenses			
Current tax		-	-
Deferred tax		-	-
Total tax expense		-	-
(Loss) for the period		9	(2,60,369)

The accompanying notes are an integral part of the financial statements.

for and on behalf of the Board of Directors of Biocon Pharma Ireland Limited

Kiran Mazumdar-Shaw
Director
DIN: 00347229

John Shaw
Director
DIN: 00347250

BIOCON PHARMA IRELAND LIMITED
STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED MARCH 31,2022
(All amounts in EURO, except share data and unless otherwise stated)

A. Equity share capital	March 31,2022	March 31, 2021
Opening balance	1	-
Changes in equity share capital during the period	7,75,000	1
Closing balance	7,75,001	1

B. Other equity

Particulars	Other equity	Total other equity
	Retained earnings	
Balance as at April 01, 2020	(2,05,916)	(2,05,916)
Loss for the period	(2,60,369)	(2,60,369)
Other comprehensive income	-	-
Total comprehensive income for the period	(2,60,369)	(2,60,369)
Balance as at March 31, 2020	(4,66,285)	(4,66,285)
Share application money pending allotment		
Loss for the year	9	9
Other comprehensive income	-	-
Total comprehensive income for the year	9	9
Balance as at March 31,2022	(4,66,276)	(4,66,276)

The accompanying notes are an integral part of the financial statements.

for and on behalf of the Board of Directors of Biocon Pharma Ireland Limited

Kiran Mazumdar-Shaw
Director
DIN: 00347229

John Shaw
Director
DIN: 00347250

BIOCON PHARMA IRELAND LIMITED
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31,2022
(All amounts are in EURO, except share data and per share data, unless otherwise stated)

	Year ended March 31, 2022	Period ended Mar 31, 2021
I Cash flows from operating activities		
Loss after tax	9	(2,60,369)
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Interest expense	-	2,631
Operating profit before working capital changes	<u>9</u>	<u>(2,57,738)</u>
Movements in working capital		
(Increase)/Decrease in loans and advances and other assets	446	-
Increase/ (decrease) in trade payable, other liabilities and provisions	1,14,558	4,700
Increase/ (decrease) in trade receivables	(2,65,707)	-
Cash generated from operations	(1,50,694)	(2,53,038)
Direct taxes paid, net	-	-
Net cash flow from operating activities	<u>(1,50,694)</u>	<u>(2,53,038)</u>
II Cash flows from investing activities		
Purchase of intangible assets	(65,875)	-
Net cash flow from / (used) in investing activities	<u>(65,875)</u>	<u>-</u>
III Cash flows from financing activities		
Issue of Share capital	-	1
Proceeds/(repayment) of long-term borrowings	-	2,98,158
Interest paid	-	-
Net cash flow used in financing activities	<u>-</u>	<u>2,98,159</u>
IV Net increase in cash and cash equivalents (I + II + III)	(2,16,569)	45,121
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the period	2,18,424	-
VII Cash and cash equivalents at the end of the period (IV + V + VI)	<u>1,855</u>	<u>45,121</u>
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	1,855	2,18,424
Cash on hand	-	-
Total cash and cash equivalents	<u>1,855</u>	<u>2,18,424</u>

The accompanying notes are an integral part of the financial statements.

As per our report of even date attached

for B S R & Co. LLP

for and on behalf of the Board of Directors of Biocon Pharma Ireland Limited

Kiran Mazumdar-Shaw
Director
DIN: 00347229

John Shaw
Director
DIN: 00347250

BIOCON PHARMA IRELAND LIMITED

Notes to the financial statements for the year ended March 31,2022

(All amounts in EURO, except share data and unless otherwise stated)

	<u>March 31,2022</u>	<u>March 31, 2021</u>
<u>2.(i) Cash and cash equivalents</u>		
Balances with banks:		
On current accounts	1,855	2,18,424
Total cash and cash equivalent	<u>1,855</u>	<u>2,18,424</u>
<u>2.(i) Other Financial Asset</u>		
Other receivables	2,65,707	-
<u>3. Other assets</u>		
(a) Current		
Balances with statutory / government authorities	300	746
Prepayments	-	-
	<u>300</u>	<u>746</u>
<u>4(a). Equity share capital</u>		
Authorised		
5,000,000 shares of EUR 1 per share	<u>50,00,000</u>	<u>50,00,000</u>
Issued, subscribed and fully paid-up		
775,001 shares (March 31, 2020: 1 share) of EUR 1 per share	<u>7,75,001</u>	<u>7,75,001</u>
<u>4(b). Other equity</u>		
Retained earnings		
The amount that can be distributed by the Company as dividends to its equity shareholders.		
<u>5. Borrowings</u>		
<u>Non-Current</u>		
Loan from fellow subsidiaries	-	-
	<u>-</u>	<u>-</u>
<u>4. Other liabilities</u>		
(a) Current		
Statutory taxes and dues payable	-	-
	<u>-</u>	<u>-</u>
<u>5. Trade payables</u>		
Trade payables	1,39,916	25,358
	<u>1,39,916</u>	<u>25,358</u>

BIOCON PHARMA IRELAND LIMITED**Notes to the financial statements for the period ended March 31, 2022****(All amounts in EURO, except share data and unless otherwise stated)**

	<u>Year ended</u> <u>March 31, 2022</u>	<u>Year ended</u> <u>March 31, 2021</u>
<u>16. Other income</u>		
Foreign exchange gain, net	9	-
	<u>9</u>	<u>-</u>
<u>8. Employee benefits expense</u>		
Salaries, wages and bonus	-	-
Staff welfare expenses	-	-
	<u>-</u>	<u>-</u>
<u>8. Finance Cost</u>		
Interest on Loan	-	-
	<u>-</u>	<u>-</u>
<u>6. Other expenses</u>		
Communication expenses	-	-
Travelling and conveyance	-	-
Professional charges	-	1,10,783
Payments to auditors	-	-
Power and fuel	-	-
Insurance	-	-
Rates, taxes and fees, net of refunds of taxes	-	-
Research & development expenses	-	1,48,093
Miscellaneous expenses	-	1,493
	<u>-</u>	<u>2,60,369</u>